Hunan Jingfeng Pharmaceutical Co

Hunan Jingfeng Pharmaceutical Co EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Hunan Jingfeng Pharmaceutical Co (000908.SZ) as of Oct 21, 2026 is -3.40 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was 21.69 % — a change of -115.68% (lower).

EBIT/Assets

-3.40 %

YoY

-115.68%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Hunan Jingfeng Pharmaceutical Co is 2025 -3.40 % . Operating Income to Assets Ratio (EBIT/Assets) of Hunan Jingfeng Pharmaceutical Co was 2024 21.69 % . It decreases by -115.68% lower compared to the previous year.

The Hunan Jingfeng Pharmaceutical Co EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
4.88 CNY
Jan 1, 2019
-20.88 CNY
Jan 1, 2020
-41.77 CNY
Jan 1, 2021
-7.58 CNY
Jan 1, 2022
-4.65 CNY
Jan 1, 2023
-16.31 CNY
Jan 1, 2024
21.69 CNY
Jan 1, 2025
-3.40 CNY
The Hunan Jingfeng Pharmaceutical Co EBIT/Assets history
YEAREBIT/AssetsYoY
-3.40 %-115.68%
21.69 %-233.00%
-16.31 %+250.52%
-4.65 %-38.64%
-7.58 %-81.85%
-41.77 %+100.02%
-20.88 %-528.17%
4.88 %-8.00%
5.30 %-38.24%
8.58 %-28.92%
12.08 %-21.28%
15.34 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Hunan Jingfeng Pharmaceutical Co Stock analysis

What does Hunan Jingfeng Pharmaceutical Co do? Hunan Jingfeng Pharmaceutical Co., Ltd. generates revenue through the research, development, manufacture, and sale of chemical and biological drugs. Its main product categories include cardio and cerebrovascular drugs, antihypertensive and hypolipidemic drugs, orthopedic drugs, anti-tumor products, endocrine drugs, digestive system drugs, antiviral drugs, and anti-infective drugs. The company distributes these products domestically and also engages in commodity import and export trading, business management and consulting, and medical technology consulting services. Sales are primarily directed at the domestic market with no mention of international distribution channels. The firm's revenue streams are derived from pharmaceutical sales, particularly in cardiovascular, oncology, and infectious disease treatments, alongside ancillary services such as medical technology consulting. The domestic market remains the sole focus for product distribution, with no indication of export-oriented sales. The company's operations are centered on drug manufacturing and related consulting services, targeting healthcare providers and domestic consumers through established distribution networks. Hunan Jingfeng Pharmaceutical's business model emphasizes product diversity across multiple therapeutic areas, including cardiovascular, oncology, and infectious diseases. The company's revenue is driven by both direct pharmaceutical sales and ancillary consulting services, with all activities confined to the domestic market. The absence of international operations or export-focused strategies is consistent with the business description provided. Hunan Jingfeng Pharmaceutical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Hunan Jingfeng Pharmaceutical Co stock

Operating Income to Assets Ratio (EBIT/Assets) of Hunan Jingfeng Pharmaceutical Co is -3.40 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Hunan Jingfeng Pharmaceutical Co changed from 21.69 % to -3.40 %, representing a -115.68% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Hunan Jingfeng Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Hunan Jingfeng Pharmaceutical Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Hunan Jingfeng Pharmaceutical Co

All Key Metrics — Hunan Jingfeng Pharmaceutical Co